Total Payments
$1.9M
2024 Payments
$236,742
Companies
58
Transactions
2,740
Medicare Patients
1,774
Medicare Billing
$4.3M
Payment Breakdown by Category
Other$1.4M (71.4%)
Consulting$296,065 (15.6%)
Travel$191,055 (10.1%)
Food & Beverage$49,564 (2.6%)
Research$4,406 (0.2%)
Education$730.94 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.3M | 405 | 67.3% |
| Consulting Fee | $296,065 | 97 | 15.6% |
| Travel and Lodging | $191,055 | 508 | 10.1% |
| Honoraria | $52,894 | 12 | 2.8% |
| Food and Beverage | $49,564 | 1,689 | 2.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $25,500 | 6 | 1.3% |
| Unspecified | $4,406 | 3 | 0.2% |
| Education | $730.94 | 19 | 0.0% |
| Grant | $500.00 | 1 | 0.0% |
Payments by Type
General
$1.9M
2,737 transactions
Research
$4,406
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $457,131 | 686 | $0 (2024) |
| PFIZER INC. | $276,350 | 319 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $244,435 | 237 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $229,107 | 216 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $155,990 | 85 | $0 (2024) |
| Janssen Biotech, Inc. | $123,718 | 469 | $0 (2024) |
| Lilly USA, LLC | $96,596 | 98 | $0 (2024) |
| UCB, Inc. | $90,631 | 167 | $0 (2024) |
| Takeda Pharmaceuticals America, Inc. | $62,836 | 43 | $0 (2017) |
| Celltrion USA Inc. | $29,715 | 31 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $236,742 | 317 | Lilly USA, LLC ($38,400) |
| 2023 | $345,185 | 390 | AbbVie Inc. ($133,697) |
| 2022 | $297,424 | 390 | ABBVIE INC. ($82,968) |
| 2021 | $201,277 | 248 | AbbVie Inc. ($78,475) |
| 2020 | $115,791 | 124 | PFIZER INC. ($52,194) |
| 2019 | $225,255 | 423 | PFIZER INC. ($97,248) |
| 2018 | $195,182 | 400 | Janssen Scientific Affairs, LLC ($57,221) |
| 2017 | $280,888 | 448 | Janssen Scientific Affairs, LLC ($74,380) |
All Payment Transactions
2,740 individual payment records from CMS Open Payments — Page 1 of 110
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | PFIZER INC. | VELSIPITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 12/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,300.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $11.36 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/16/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Travel and Lodging | In-kind items and services | $795.34 | General |
| Category: Heart Failure | ||||||
| 12/16/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $99.76 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | PFIZER INC. | VELSIPITY (Drug) | Travel and Lodging | In-kind items and services | $54.04 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 12/12/2024 | Janssen Scientific Affairs, LLC | — | Food and Beverage | In-kind items and services | $17.89 | General |
| 12/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $10,396.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $30.66 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GATTEX (Drug) | Food and Beverage | In-kind items and services | $25.02 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/10/2024 | PFIZER INC. | VELSIPITY (Drug) | Travel and Lodging | In-kind items and services | $519.26 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 12/10/2024 | PFIZER INC. | VELSIPITY (Drug) | Travel and Lodging | In-kind items and services | $496.80 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 12/09/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $136.11 | General |
| 12/09/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $32.93 | General |
| Category: Immunology | ||||||
| 12/09/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $25.19 | General |
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $38.42 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Travel and Lodging | In-kind items and services | $86.04 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Travel and Lodging | In-kind items and services | $51.78 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Travel and Lodging | In-kind items and services | $48.94 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Travel and Lodging | In-kind items and services | $35.92 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $23.02 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $17.98 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Travel and Lodging | In-kind items and services | $13.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Travel and Lodging | In-kind items and services | $8.95 | General |
| Category: INTERNAL MEDICINE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Effects of Transient and Persistent Anti-Drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7 Year Study in Crohn's Disease | UCB, Inc. | $2,300 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $1,584 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | Eli Lilly and Company | $522.53 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 455 | 61,717 | $4.9M | $988,306 |
| 2022 | 14 | 472 | 45,295 | $5.0M | $1.3M |
| 2021 | 15 | 433 | 37,403 | $4.6M | $1.5M |
| 2020 | 13 | 414 | 48,667 | $3.1M | $519,357 |
Total Patients
1,774
Total Services
193,082
Medicare Billing
$4.3M
Procedure Codes
54
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3380 | Injection, vedolizumab, 1 mg | Office | 2023 | 23 | 39,000 | $3.3M | $624,397 | 18.8% |
| J3358 | Ustekinumab, for intravenous injection, 1 mg | Office | 2023 | 12 | 16,640 | $372,736 | $162,163 | 43.5% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 15 | 5,320 | $872,480 | $139,870 | 16.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 41 | 244 | $143,228 | $22,875 | 16.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 95 | 188 | $39,668 | $11,470 | 28.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 51 | 66 | $20,724 | $6,293 | 30.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 55 | 57 | $22,857 | $5,582 | 24.4% |
| 93976 | Ultrasound of abdomen and pelvis artery and vein blood flow | Office | 2023 | 39 | 44 | $38,896 | $4,896 | 12.6% |
| 76700 | Complete ultrasound scan of abdomen | Office | 2023 | 39 | 44 | $21,076 | $4,184 | 19.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 32 | 32 | $42,176 | $3,567 | 8.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 14 | 38 | $11,058 | $1,759 | 15.9% |
| 76857 | Limited ultrasound scan of pelvis | Office | 2023 | 39 | 44 | $15,400 | $1,250 | 8.1% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2022 | 22 | 36,300 | $3.1M | $614,802 | 19.9% |
| J3357 | Ustekinumab, for subcutaneous injection, 1 mg | Office | 2022 | 18 | 3,960 | $883,080 | $530,236 | 60.0% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 12 | 4,290 | $703,560 | $121,956 | 17.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 35 | 206 | $120,922 | $22,929 | 19.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 110 | 189 | $39,879 | $10,544 | 26.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 67 | 80 | $25,120 | $7,531 | 30.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 64 | 66 | $26,466 | $7,033 | 26.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 43 | 44 | $57,992 | $6,306 | 10.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 36 | 36 | $31,428 | $3,156 | 10.0% |
| 93976 | Ultrasound of abdomen and pelvis artery and vein blood flow | Office | 2022 | 11 | 13 | $11,492 | $1,506 | 13.1% |
| 76700 | Complete ultrasound scan of abdomen | Office | 2022 | 11 | 14 | $6,706 | $1,384 | 20.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 12 | 22 | $6,402 | $1,237 | 19.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 19 | 60 | $5,820 | $710.40 | 12.2% |
About Dr. Bincy Abraham, MD
Dr. Bincy Abraham, MD is a Gastroenterology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2007. The National Provider Identifier (NPI) number assigned to this provider is 1578767166.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bincy Abraham, MD has received a total of $1.9M in payments from pharmaceutical and medical device companies, with $236,742 received in 2024. These payments were reported across 2,740 transactions from 58 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.3M).
As a Medicare-enrolled provider, Abraham has provided services to 1,774 Medicare beneficiaries, totaling 193,082 services with total Medicare billing of $4.3M. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Gastroenterology
- Location Houston, TX
- Active Since 06/14/2007
- Last Updated 02/10/2017
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1578767166
Products in Payments
- STELARA (Biological) $321,700
- XELJANZ (Drug) $222,457
- SKYRIZI (Biological) $163,534
- Entyvio (Biological) $151,169
- ZEPOSIA (Drug) $132,112
- ENTYVIO (Biological) $120,709
- HUMIRA (Biological) $100,565
- Cimzia (Drug) $84,659
- RINVOQ (Biological) $60,947
- ZYMFENTRA (Biological) $40,482
- OMVOH (Drug) $36,998
- INJECTAFER (Drug) $28,747
- Humira (Biological) $26,082
- TREMFYA (Drug) $24,908
- VELSIPITY (Drug) $22,435
- UCERIS (Drug) $20,217
- INFLECTRA (Biological) $16,875
- SIMPONI (Biological) $12,972
- APRISO (Drug) $8,182
- REMICADE (Biological) $7,000
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Houston
Dr. Isaac Raijman, Md, MD
Gastroenterology — Payments: $1.6M
Gastroenterology $1.6M
Dr. Brooks Cash, Md, MD
Gastroenterology — Payments: $1.3M
Gastroenterology $1.3M
Dr. Mazen Noureddin, M.d, M.D
Gastroenterology — Payments: $786,099
Gastroenterology $786,099
Dr. Jason Hou, M.d, M.D
Gastroenterology — Payments: $372,514
Gastroenterology $372,514
Kalpesh Patel, Md, MD
Gastroenterology — Payments: $313,187
Gastroenterology $313,187
Dr. Nirav Thosani, Md, MD
Gastroenterology — Payments: $251,409
Gastroenterology $251,409